WallStreetZenWallStreetZen

NASDAQ: VCNX
Vaccinex Inc Stock

$7.45-0.10 (-1.32%)
Updated Mar 27, 2024
VCNX Price
$7.45
Fair Value Price
$1.85
Market Cap
$6.65M
52 Week Low
$7.16
52 Week High
$100.80
P/E
-0.09x
P/B
-1.72x
P/S
6.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$795.00k
Earnings
-$22.01M
Gross Margin
100%
Operating Margin
-2,768.81%
Profit Margin
-2,768.8%
Debt to Equity
-1.66
Operating Cash Flow
-$18M
Beta
0.41
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VCNX Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VCNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VCNX ($7.45) is overvalued by 301.66% relative to our estimate of its Fair Value price of $1.85 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VCNX ($7.45) is not significantly undervalued (301.66%) relative to our estimate of its Fair Value price of $1.85 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VCNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VCNX due diligence checks available for Premium users.

Be the first to know about important VCNX news, forecast changes, insider trades & much more!

VCNX News

Valuation

VCNX fair value

Fair Value of VCNX stock based on Discounted Cash Flow (DCF)
Price
$7.45
Fair Value
$1.85
Overvalued by
301.66%
VCNX ($7.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VCNX ($7.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VCNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VCNX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.09x
Industry
14.3x
Market
44.45x

VCNX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.72x
Industry
6.2x

VCNX's financial health

Profit margin

Revenue
$20.0k
Net Income
-$4.9M
Profit Margin
-24,560%
VCNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VCNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.6M
Liabilities
$6.4M
Debt to equity
-1.66
VCNX's short-term liabilities ($6.36M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCNX's short-term assets ($2.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCNX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VCNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.1M
Investing
-$18.0k
Financing
$1.3M
VCNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VCNX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VCNX$6.65M-1.32%-0.09x-1.72x
BRTX$6.56M-0.50%-0.34x0.51x
ATXI$6.77M+1.32%-0.16x4.28x
SNGX$6.39M+2.88%-0.77x2.53x
TRVN$6.96M+3.61%-0.17x1.96x

Vaccinex Stock FAQ

What is Vaccinex's quote symbol?

(NASDAQ: VCNX) Vaccinex trades on the NASDAQ under the ticker symbol VCNX. Vaccinex stock quotes can also be displayed as NASDAQ: VCNX.

If you're new to stock investing, here's how to buy Vaccinex stock.

What is the 52 week high and low for Vaccinex (NASDAQ: VCNX)?

(NASDAQ: VCNX) Vaccinex's 52-week high was $100.80, and its 52-week low was $7.16. It is currently -92.61% from its 52-week high and 4.04% from its 52-week low.

How much is Vaccinex stock worth today?

(NASDAQ: VCNX) Vaccinex currently has 892,448 outstanding shares. With Vaccinex stock trading at $7.45 per share, the total value of Vaccinex stock (market capitalization) is $6.65M.

Vaccinex stock was originally listed at a price of $2,389.80 in Aug 9, 2018. If you had invested in Vaccinex stock at $2,389.80, your return over the last 5 years would have been -99.69%, for an annualized return of -68.47% (not including any dividends or dividend reinvestments).

How much is Vaccinex's stock price per share?

(NASDAQ: VCNX) Vaccinex stock price per share is $7.45 today (as of Mar 27, 2024).

What is Vaccinex's Market Cap?

(NASDAQ: VCNX) Vaccinex's market cap is $6.65M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vaccinex's market cap is calculated by multiplying VCNX's current stock price of $7.45 by VCNX's total outstanding shares of 892,448.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.